View live charts, options flow & technicals for Moderna, Inc. →
Open Dashboard
Moderna, Inc. (MRNA) is a healthcare company in the biotechnology industry with $2.23B in trailing revenue — analyst consensus: hold.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Key Statistics
Market Cap
$72.70B
Revenue (TTM)
$2.23B
EPS (TTM)
$-7.96
EPS (Fwd est.)
$-4.47
Employees
4,700
Forward P/E
-40.75
Price / Sales
32.63
Price / Book
10.75
EV / EBITDA
-31.37
Beta (5Y)
1.11
Analyst Consensus
Consensus
Hold
Analyst Price Target
-34.3% downside
Target: $119.56
Annual Revenue & Net Income
RevenueNet Income
'22
$18.88B
$8.36B
'23
$6.75B
$-4.71B
'24
$3.20B
$-3.56B
'25
$1.92B
$-2.82B
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$-1.97
$-2.06
Beat (+4.3%)
Apr 2026
$-3.40
$-3.88
Beat (+12.4%)
Feb 2026
$-2.11
$-2.64
Beat (+20.2%)
Nov 2025
$-0.51
$-2.16
Beat (+76.4%)
Next Earnings Report
Moderna, Inc. is next expected to report earnings on 05 Nov 2026.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses inclu…
What is MRNA's market cap?
Moderna, Inc. has a market capitalization of approximately $72.70B.
How much revenue does MRNA generate?
Moderna, Inc. generated $2.23B in trailing 12-month revenue.
What do analysts say about MRNA?
The analyst consensus rating for Moderna, Inc. is hold, with a mean price target of $119.56. That implies -34.3% upside from the current price.
When does MRNA report earnings?
Moderna, Inc. is next scheduled to report earnings on 05 Nov 2026.
Does MRNA pay a dividend?
Moderna, Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Moderna, Inc. on Apsis Markets.